Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension

@article{Narine2005CostminimizationAO,
  title={Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension},
  author={Lutchmie Narine and L K Hague and J. H. Walker and Colin Vicente and Robert J. Schilz and Olivier Desjardins and Thomas R Einarson and Michael Iskedjian},
  journal={Current Medical Research and Opinion},
  year={2005},
  volume={21},
  pages={2007 - 2016}
}
ABSTRACT Introduction: Idiopathic pulmonary arterial hypertension (IPAH) is associated with substantial morbidity and mortality. Treprostinil was compared to epoprostenol for the economic impact of treating IPAH patients who failed or were not candidates for bosentan. Methods: The model was a cost-minimization analysis, assuming clinical equivalence was achieved by proper dosing of both drugs, in terms of survival and surrogate measures. Two theoretical cohorts of 270 patients were treated with… Expand
Cost-Utility of Treatments for Pulmonary Arterial Hypertension
TLDR
The results from this analysis are a tool to help guide clinicians in deciding which PAH medications to use; however, the final decisions should be individualized because the effectiveness of therapy, resulting utilities and acceptable costs will differ with each patient. Expand
Cost effectiveness of prostacyclins in pulmonary arterial hypertension
TLDR
Initiating prostacyclin treatment with iloprost in patients with PAH, functional class III of the NYHA, is the less costly alternative for the NHS in Spain, with a good efficacy profile when compared with the other alternatives. Expand
Pharmacoeconomic evidence of bosentan for pulmonary arterial hypertension
TLDR
Economic modeling suggests that the cost–effectiveness of bosentan is similar to that of ambrisentan, not as cost effective as sildenafil and more cost effective than iloprost. Expand
Resource utilization at the time of prostacyclin initiation in children in pulmonary arterial hypertension: a multicenter analysis
TLDR
Treprostinil initiation has been increasing and is associated with less resource utilization and lower cost compared to epoprostenol initiation and post-discharge outcome data are needed to fully inform decision-making about the relative benefits of parental prostacyclin drug choice. Expand
Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review.
TLDR
Clinical studies have demonstrated that the 2 prostanoids available for IV administration in the United States, epoprostenol and treprostinil, improve exercise capacity, dyspnea, and cardiopulmonary hemodynamics in patients with PAH. Expand
Long‐term follow‐up of portopulmonary hypertension: Effect of treatment with epoprostenol
  • O. Fix, N. Bass, T. de Marco, R. Merriman
  • Medicine
  • Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2007
TLDR
Long‐term epoprostenol therapy greatly improves pulmonary hemodynamics in patients with PPHTN, and survival seemed not to differ between treatment groups. Expand
Current and Emerging Therapies in Pulmonary Arterial Hypertension: Focus on Treprostinil
TLDR
The pharmacokinetics, dosing, metabolism, and side effects of treprostinil in its various forms and overall place in the treatment of PAH are reviewed. Expand
Optimal Use of Treprostinil in Pulmonary Arterial Hypertension
TLDR
Intravenous treprostinil improves exercise capacity, functional class and haemodynamics in patients with PAH, over the period of 12 weeks, and whether the effect remains clinically relevant beyond 12 weeks is not known; a longer follow-up would be required to investigate this. Expand
Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension
TLDR
The economic burden of patients with PAH is substantial, while the paucity of comprehensive country-specific evidence in this area and the lack of reports on indirect costs of PAH warrant researchers’ concern, especially in China. Expand
Trends in Pediatric Pulmonary Hypertension–Related Hospitalizations in the United States from 2000–2009
TLDR
Overall mortality for PH-related hospitalizations was greater than that for hospitalizations not associated with PH, but mortality is decreasing over time, and mortality is improving over time. Expand
...
1
2
...

References

SHOWING 1-10 OF 38 REFERENCES
Treatment of pulmonary arterial hypertension: a preliminary decision analysis.
TLDR
Treatment with bosentan is more cost-effective than treatment with either treprostinil or epoprostenol and a net improvement in quality-adjusted survival may be expected. Expand
Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy
TLDR
Intravenous epoprostenol improves long-term survival in PPH and is significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data. Expand
Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension
TLDR
Patients with PAH can be safely transitioned from treatment with IV epoprostenol to subcutaneous treprostinil, and all patients reported an improved sense of comfort and well-being. Expand
Medical therapy of pulmonary hypertension. Conventional therapies.
TLDR
Although significant improvements in quality of life and survival rate have been obtained with prostacyclin therapy, and better perspectives now are offered with atrial septostomy and lung transplantation, conventional therapy also has evolved. Expand
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.
TLDR
Chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension and significantly improved indices of dyspnea, signs and symptoms of pulmonary hypertension, and hemodynamics. Expand
Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension.
TLDR
Treatment for pulmonary arterial hypertension should aim to provide vasodilation of the pulmonary arteries, treat right ventricular failure, improve functional capacity and quality of life, and improve survival, if possible, and an estimation of vasoresponsiveness together guide treatment. Expand
Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.
TLDR
Long-term follow-up of this single-center patient group demonstrated improved long-term survival during epo therapy compared with that in historical control subjects and confirms predicted improved outcomes based on shorter follow- up periods. Expand
Current and Emerging Therapy for Primary Pulmonary Hypertension
TLDR
Clinical data and experience support the use of epoprostenol; however, in patients at risk or considered unsuitable candidates, bosentan may become a preferred option; until additional studies and experience with these agents become available, calcium-channel blockers remain the first option for therapy. Expand
Medical treatment of primary pulmonary hypertension: a bridge to transplantation?
  • S. Rich
  • Medicine
  • The American journal of cardiology
  • 1995
TLDR
The role of the various medical treatment modalities, and the ideal timing of lung transplantation, is an issue that is continuing to evolve as improvements in all treatments develop. Expand
BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION
A BSTRACT Background Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exerciseExpand
...
1
2
3
4
...